Literature DB >> 11727859

Polycystic ovary syndrome and cancer.

A Balen1.   

Abstract

The polycystic ovary syndrome (PCOS) is the most common endocrine disturbance affecting women, but disagreements in diagnostic criteria make it difficult to compare epidemiological studies on long-term health risks such as cancer. The association between PCOS and endometrial adenocarcinoma has been reported for many years. Although the degree of risk has not been clearly defined, it is generally accepted that for women with PCOS who experience symptoms of amenorrhoea or oligomenorrhoea, the induction of artificial withdrawal bleeds to prevent endometrial hyperplasia is prudent management. Studies examining the relationship between PCOS and breast carcinoma have not always identified a significantly increased risk, although one recent study examined the standardized mortality rate (SMR) calculated for patients with PCOS compared with the normal population and found that the SMR for all neoplasms was 0.91 (95% CI 0.60-1.32) and for breast cancer 1.48 (95% CI 0.79-2.54). Few studies have addressed the possibility of an association between polycystic ovaries and ovarian cancer, and the results are conflicting and generally reassuring.

Entities:  

Mesh:

Year:  2001        PMID: 11727859     DOI: 10.1093/humupd/7.6.522

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  29 in total

1.  Associations between vitamin D levels and polycystic ovary syndrome phenotypes.

Authors:  Erin M Davis; Jennifer D Peck; Karl R Hansen; Barbara R Neas; LaTasha B Craig
Journal:  Minerva Endocrinol       Date:  2018-04-12       Impact factor: 2.184

2.  Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome.

Authors:  A Villavicencio; A Goyeneche; C Telleria; K Bacallao; F Gabler; A Fuentes; M Vega
Journal:  Gynecol Oncol       Date:  2009-07-23       Impact factor: 5.482

Review 3.  Cross-sex hormone therapy for gender dysphoria.

Authors:  B Fabris; S Bernardi; C Trombetta
Journal:  J Endocrinol Invest       Date:  2014-11-18       Impact factor: 4.256

4.  Evidence for statin therapy in polycystic ovary syndrome.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Ther Adv Endocrinol Metab       Date:  2010-02       Impact factor: 3.565

5.  Polycystic ovary syndrome: validated questionnaire for use in diagnosis.

Authors:  Sue D Pedersen; Sony Brar; Peter Faris; Bernard Corenblum
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

Review 6.  Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Rebecca J Mullan; Vishnu Sundaresh; Amy T Wang; Patricia J Erwin; Corrine Welt; David Ehrmann; Victor M Montori; Mohammad Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

7.  Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome.

Authors:  Jin Yeong Kim; Haengseok Song; Hyunjoo Kim; Hee Jung Kang; Jin Hyun Jun; Sung Ran Hong; Mi Kyoung Koong; In Sun Kim
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 8.  Current understanding of risk factors for ovarian cancer.

Authors:  Thanasak Sueblinvong; Michael E Carney
Journal:  Curr Treat Options Oncol       Date:  2009-07-15

9.  Challenging Regimen for Long-Term Conservative Treatment of Endometrial Adenocarcinoma in Young Women: A Case Report and Review of the Literature.

Authors:  Prasong Tanmahasamut; Thanyarat Wongwananuruk
Journal:  Case Rep Oncol       Date:  2010-10-25

10.  A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xing-Wei Liang; Zhen-Bo Wang; Zhao-Yi Wang; Jie Qiao; Heide Schatten; Qing-Yuan Sun
Journal:  Reprod Biol Endocrinol       Date:  2009-09-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.